Stem cells hold a great promise for the creation of new stem cell therapies for many untreatable diseases. Stem cell therapy, or regenerative medicine, promotes the repair response of diseased, dysfunctional, or injured tissues using stem cells and their derivatives. Such therapies can be used to treat autoimmune, neurological, inflammatory, and orthopedic conditions and traumatic injuries. Today, doctors routinely use stem cells to treat patients with aforementioned disorders.
Market Statistics:
The Global Stem Cell Manufacturing Market is estimated to account for US$ 9672.0 Mn in terms of value by the end of 2022.
Drivers:
Increase in focus on the development of stem cell therapies owing to therapeutic potential of stem cells is expected to propel growth of the global stem cell manufacturing market during the forecast period. For instance, players in the market are focusing on introducing new stem cell therapies due to increase in burden of both chronic and neurological disorders worldwide. In February 2022, the Government of India conducted stem cell research through various Departments or Institutions by supporting basic as well as clinical research through national funding agencies. The work done in this field has resulted in the establishment of state-of-art infrastructure at over 40 premier health research and educational institutes in addition to supporting industry initiatives in India.
Opportunities:
Increase in prevalence of chronic and neurological disorders is expected to offer significant growth opportunities for players in the global stem cell manufacturing market. For instance, doctors now routinely use stem cells that come from bone marrow and/or blood in transplant procedures to treat people with cancer and disorders of the blood and immune system. Thus, with the rise in burden of cancer, the use of stem cells is also increasing with the rapid pace. According to the American Cancer Society, in 2022, there will be an estimated 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the United States. Thus, players in the market are focusing on introducing new stem cell therapies for the cancer treatment.
Restraints:
High cost of stem cell manufacturing and high operational costs associated with stem cell banking are major factors expected to hinder growth of the stem cell manufacturing market. For instance, Stem cells hold great promise for new treatments. Although stem cell therapies are contributing to the well-being of individuals suffering from incurable diseases, the cost of stem cell manufacturing acts as a constraint in the growth of the studied market.
Stem Cell Manufacturing Market - Impact of Coronavirus (Covid-19) Pandemic:
Stem cell therapies can play an important role in the COVID-19 treatment, and are being suggested to treat COVID-19. In short, the pandemic has had a positive impact on the stem cell manufacturing market. Therefore, several market players (pharma companies) and government organizations and universities are involved in research studies associated with stem cells. In April 2022, the U.S. Food and Drug Administration (FDA) granted clearance to BioCardia’s Investigational New Drug (IND) application to commence Phase I/II stem cell clinical trial of BCDA-04 in adults recovering from COVID-19-linked acute respiratory distress syndrome (ARDS).
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/stem-cell-manufacturing-market-5381
Key Takeaways:
The global stem cell manufacturing market was valued at US$ 8584.2 Mn in 2021 and is forecast to reach a value of US$ 20428.1 Mn by 2028 at a CAGR of 13.3% between 2022 and 2028.
Among type, product segment held dominant position in the global stem cell manufacturing market in 2021, accounting for 81.5% share in terms of value, increasing approval and launch of new products is expected to propel growth of the segment during the forecast period.
Market Trends:
With the breakthrough in stem cells, there are an increasing number of clinical trials worldwide. Moreover, favorable government initiatives and government support for research and development of regenerative medicine have increased demand for stem cell manufacturing. Stem cell therapies can be used to treat variety of life-threatening disorders. Thus, with the increase in burden of such diseases, the number of clinical trials and R&D activities are also increasing rapidly. This trend is expected to continue during the forecast period, driving the market growth.
Competitive Landscape:
Major players operating in the global stem cell manufacturing market include
TAKARA BIO Inc., PHARMICELL Co., Ltd., MEDIPOST Co., Holostem Terapie Avanzate S.r.l, Bio-Rad Laboratories, Anterogen Co., Ltd., Osiris Therapeutics, Inc (Smith & Nephew PLC), Minaris Regenerative Medicine (Hitachi Chemical Co., Ltd.), Nikon CeLL Innovation Co. Ltd. (Nikon Corporation), Medinet Co. Ltd., Cell and Gene Therapy Catapult, Bio Elpida, Miltenyi Biotec, Pluristem Therapeutics Inc., Thermo Fischer Scientific, Merck Group, Corning Incorporated, Stem Cell Technologies, Lonza Group, Becton, Dickinson and Company, Sartorius, and Cellular Dynamics (Fujifilm Holdings Corporation, among others.
Recent Developments:
In July 2020, Becton, Dickinson and Company (BD) and the Biomedical Advanced Research and Development Authority (BARDA) to develop manufacturing infrastructure for mass vaccination for the present pandemic.
In May 2020, Lonza Group and Noga Therapeutics teamed up for the development of an innovative cocoon platform in autologous Lentiviral Gene Therapy.
In August 2019, Sartorius Stedim Biotech announced the launch of comprehensive services that offer the manufacture of GMP master and working cell banks for mammalian cell suspensions under GMP conditions.
